Nurix Therapeutics, Inc.
NRIX
$9.63
$0.101.05%
NASDAQ
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 88.38M | 56.42M | 54.55M | 56.42M | 62.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 88.38M | 56.42M | 54.55M | 56.42M | 62.30M |
| Cost of Revenue | 270.46M | 241.29M | 221.63M | 204.12M | 196.50M |
| Gross Profit | -182.08M | -184.87M | -167.08M | -147.70M | -134.19M |
| SG&A Expenses | 48.37M | 45.80M | 45.94M | 46.01M | 44.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 318.84M | 287.09M | 267.58M | 250.13M | 241.41M |
| Operating Income | -230.45M | -230.67M | -213.03M | -193.70M | -179.11M |
| Income Before Tax | -206.47M | -208.22M | -193.30M | -176.71M | -164.82M |
| Income Tax Expenses | 850.00K | 180.00K | 270.00K | 262.00K | 180.00K |
| Earnings from Continuing Operations | -207.32 | -208.40 | -193.57 | -176.98 | -165.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -207.32M | -208.40M | -193.57M | -176.98M | -165.00M |
| EBIT | -230.45M | -230.67M | -213.03M | -193.70M | -179.11M |
| EBITDA | -222.22M | -222.35M | -205.01M | -186.40M | -172.25M |
| EPS Basic | -2.61 | -2.81 | -2.89 | -2.91 | -2.92 |
| Normalized Basic EPS | -1.63 | -1.75 | -1.80 | -1.82 | -1.82 |
| EPS Diluted | -2.61 | -2.81 | -2.89 | -2.91 | -2.92 |
| Normalized Diluted EPS | -1.63 | -1.75 | -1.80 | -1.82 | -1.82 |
| Average Basic Shares Outstanding | 318.63M | 297.13M | 268.47M | 244.73M | 226.34M |
| Average Diluted Shares Outstanding | 318.63M | 297.13M | 268.47M | 244.73M | 226.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |